Single-Tablet Bictegravir-Lenacapavir Formulation for HIV Adherence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV treatment regimens involving multiple tablets are difficult for patients to adhere to consistently, leading to potential virologic failure due to complex dosing schedules and high pill burden, necessitating a simpler, single-tablet combination therapy with bictegravir and lenacapavir to improve patient compliance and reduce treatment complexity.
Innovation Solution
Formulation of bictegravir and lenacapavir into a single tablet, with specific dosages and configurations such as monolayer and bilayer tablets, to maintain comparable or improved pharmacokinetic properties and reduce pill burden, ensuring effective therapeutic outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple tablets are used for HIV treatment, then therapeutic efficacy is maintained, but patient adherence deteriorates due to complex dosing schedules and high pill burden
Solution Approach 1:
The patent combines bictegravir and lenacapavir into a single fixed-dose combination tablet, merging two separate medications into one unified dosage form. This reduces the number of tablets patients must take and simplifies the dosing schedule, directly addressing the adherence problem while maintaining the therapeutic efficacy of both agents
2Reliability
If multiple tablets are used for HIV treatment, then comprehensive antiviral coverage is achieved, but treatment complexity increases
Solution Approach 1:
The fixed-dose combination tablet merges bictegravir (an integrase inhibitor) and lenacapavir (a capsid inhibitor) into a single dosage unit, reducing treatment complexity by eliminating the need to manage multiple separate tablets and dosing schedules while preserving comprehensive antiviral coverage through the complementary mechanisms of action of both drugs
Data Source
AI summary
The disclosure provides a solid oral dosage form comprising bictegravir or a pharmaceutically acceptable salt thereof, and lenacapavir or a pharmaceutically acceptable salt thereof.